Numerous studies have demonstrated that aberrant activation of the PI3K/Akt pathway is involved in the pathological process of bladder cancer, and its inhibition has become a useful therapy for bladder cancer 32, 33. This evidence concerns the gene AKT1 and urinary bladder carcinoma.